VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q2 2023. The put-call ratio across all filers is 4.14 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,102,799 | -0.3% | 21,632 | -2.4% | 0.00% | 0.0% |
| Q2 2023 | $1,106,471 | +70.6% | 22,156 | +28.0% | 0.00% | – |
| Q1 2023 | $648,704 | -26.7% | 17,308 | -6.3% | 0.00% | -100.0% |
| Q4 2022 | $885,253 | +158.8% | 18,462 | +29.4% | 0.00% | – |
| Q3 2022 | $342,000 | +8.6% | 14,272 | -1.6% | 0.00% | – |
| Q2 2022 | $315,000 | +22.6% | 14,497 | +43.2% | 0.00% | – |
| Q3 2021 | $257,000 | -3.0% | 10,121 | -14.0% | 0.00% | – |
| Q2 2021 | $265,000 | +18.8% | 11,762 | +4.0% | 0.00% | – |
| Q1 2021 | $223,000 | -20.1% | 11,314 | +7.6% | 0.00% | – |
| Q4 2020 | $279,000 | – | 10,517 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |